Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM
Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM
This morning, Michael Clayman, M.D., CEO of Flexion Therapeutics (Nasdaq: FLXN), appeared live on Fox Business News to talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM (FX006) which is being evaluated as a potential new therapy for OA related knee pain. A link to Mike’s interview can be found below:
http://finance.yahoo.com/video/developing-alternatives-opioids-relieve-pain-130004965.html
Related News
Sensorion Announces Approval of Clinical Trial Application in France for SENS-601, Its Investigational Gene Therapy for the Treatment of GJB2-Related Hearing Loss
Biotalys Secures Product Registration in California for EVOCA®, Strengthening Regulatory Pathway for Its Lead Asset EVOCA NG
Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
Medtronic announces strategic investment in Pi-Cardia to accelerate innovation for complex TAVR
AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality Officer